Evaluation of Overall Compliance and Duration of Zomacton® Treatment With the Zomajet® Needle-free Device

CompletedOBSERVATIONAL
Enrollment

87

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

October 31, 2011

Study Completion Date

November 30, 2011

Conditions
Turner's SyndromeHuman Growth Hormone Deficiency
Interventions
DRUG

Somatropin

4 mg or 10 mg delivered by needle-free device

Trial Locations (17)

Unknown

Investigational site, Angers

Investigational site, Antibes Juan Les Pins

Investigational site, Bordeaux

Investigational site, Brive-la-Gaillarde

Investigational site, Hyères

Investigational site, Le Mans

Investigational site, Lille

Investigational site, Lisieux

Investigational site, Montivilliers

Investigational site, Montpellier

Investigational site, Nice

Investigational site, Nieul-sur-Mer

Investigational site, Paris

Investigational site, Puyricard

Investigational site, Tarbes

Investigational site, Toulon

Investigational site, Toulouse

Sponsors
All Listed Sponsors
lead

Ferring Pharmaceuticals

INDUSTRY

NCT01306357 - Evaluation of Overall Compliance and Duration of Zomacton® Treatment With the Zomajet® Needle-free Device | Biotech Hunter | Biotech Hunter